title: [Effect of brentuximab vedotin combined with chlormethine hydrochloride on the treatment of 6 patients with relapsed and refractory Hodgkin lymphoma].
abstract: OBJECTIVE
  To observe the clinical efficacy and side effects of brentuximab vedotin (BV) plus chlormethine hydrochloride (CH) in patients with relapsed and refractory Hodgkin lymphoma (HL) after failure with BV alone.
  
  
  METHODS
  From March, 2014 to December, 2014, 6 patients who failed with BV monotherapy were enrolled in this study. The chemotherapy regimen consisted of BV (1.2-1.8 mg/kg, iv. gtt, d1) and CH (6 mg/m2, iv. gtt, d1) was given for 3 weeks as one course, and all patients received about 3-8 courses of chemotherapy, with an median of 4 courses. Clinical efficacy and adverse events were assessed and observed by radiographic examination and serological detection.
  
  
  RESULTS
  Among 6 patients, the overall response rate was 100% with 2 complete remission and 4 partial remission. The main adverse events were grade I (2 patients) and IV (2 patients) bone marrow depression, grade II (2 patients)gastrointestinal reaction, grade I (1 patient) increase of transaminase and myocardial enzyme and grade I (1 patient) mouth ulcers.
  
  
  CONCLUSIONS
  The combination of BV and CH in the treatment of relapsed and refractory HL after failure with BV alone was high effective and the toxicities were well tolerable.
authors: The General Hospital of People's Liberation Armyl, Beijing 100853, China.
authors: Zhigang
authors: Z
authors: Cao
authors: The General Hospital of People's Liberation Armyl, Beijing 100853, China.
authors: Zhihong
authors: Z
authors: Wang
authors: The General Hospital of People's Liberation Armyl, Beijing 100853, China.
authors: Junzhong
authors: J
authors: Sun
authors: The General Hospital of People's Liberation Armyl, Beijing 100853, China.
authors: Chaojin
authors: C
authors: Peng
authors: The General Hospital of People's Liberation Armyl, Beijing 100853, China.
authors: Shaomei
authors: S
authors: Feng
authors: The General Hospital of People's Liberation Armyl, Beijing 100853, China.
authors: Xiaoyan
authors: X
authors: Zhou
authors: The General Hospital of People's Liberation Armyl, Beijing 100853, China.
authors: Qingming
authors: Q
authors: Yang
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008466:Mechlorethamine / Q000627:therapeutic use*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D018796:Immunoconjugates; D008466:Mechlorethamine; D000079963:Brentuximab Vedotin